Regulation 30 dislosure
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sandu Pharmaceuticals' board approved standalone unaudited results for Q1 FY26 (quarter ended June 30, 2025). Revenue from operations stood at Rs 1,665.90 lakhs vs Rs 1,704.54 lakhs in Q1 FY25, a slight decline of about 2.3%. Profit after tax rose to Rs 22.33 lakhs from Rs 16.69 lakhs, a growth of roughly 34% year-on-year, with EPS of Rs 0.23 vs Rs 0.17. The statutory auditor issued an unmodified (clean) limited review opinion on the results. The board set September 18, 2025 as the record date for dividend eligibility, with the 40th AGM scheduled for September 30, 2025 via video conferencing. The company has no subsidiaries, so no consolidation is required. Approval is being sought from shareholders for continuation of material related party transactions with Sandu Brothers Private Limited and for continuation of Shri. Vijay Kajarekar as CFO past the age of 70.
Mixed signals for shareholders: a modest dip in quarterly revenue, but a strong ~34% jump in net profit suggests margin improvement. The dividend record date and AGM date are confirmed. The related party transaction continuation with the promoter-group entity Sandu Brothers is a governance item that shareholders should review before the AGM.